Phase 3 Clinical Trials With Primary Completion Dates in August 2020
This is a list of Phase 3 trials with primary completion dates in August 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2020-08-01 | Phase 3 | NCT03121586 | Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia |
| ADMS | Adamas Pharmaceuticals, Inc. | 2020-08-01 | Phase 3 | NCT03567057 | A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment |
| ARDS | Aridis Pharmaceuticals, Inc. | 2020-08-01 | Phase 3 | NCT03816956 | Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 |
| CHMA | Chiasma, Inc. | 2020-08-01 | Phase 3 | NCT02685709 | Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly |
| DOVA | Dova Pharmaceuticals, Inc. | 2020-08-01 | Phase 3 | NCT03471078 | Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers |
| ERYP | ERYTECH Pharma S.A. | 2020-08-01 | Phase 3 | NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC |
| EXEL | Exelixis, Inc. | 2020-08-01 | Phase 3 | NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy |
| INTP | Integrated Pharmaceuticals, Inc. | 2020-08-01 | Phase 3 | NCT03588429 | The Ratio of Hypnotic to Analgesic Potency of Volatile Anesthetics |
| MDXG | MiMedx Group, Inc. | 2020-08-01 | Phase 3 | NCT03414268 | Micronized dHACM Injectable for the Treatment of Plantar Fasciitis |
| OMER | Omeros Corporation | 2020-08-01 | Phase 3 | NCT03608033 | Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy |
| SAGE | Sage Therapeutics, Inc. | 2020-08-01 | Phase 3 | NCT03665038 | A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD) |
| SUPN | Supernus Pharmaceuticals, Inc. | 2020-08-01 | Phase 3 | NCT04016779 | Evaluation of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder |
| TLRY | Tilray, Inc. | 2020-08-01 | Phase 3 | NCT03549819 | Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study |
| VNDA | Vanda Pharmaceuticals Inc. | 2020-08-01 | Phase 3 | NCT04327661 | Motion Syros: A Randomized Study Investigating the Efficacy of Tradipitant in Treating Motion Sickness |
| VNDA | Vanda Pharmaceuticals Inc. | 2020-08-01 | Phase 3 | NCT04326426 | ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection |